Melatonin and sleep in aging population.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or pooled meta-analytic data.
PubMed 16183237 · doi:10.1016/j.exger.2005.08.009
What was done
This narrative review evaluated literature regarding pineal melatonin secretion in relation to the light-dark cycle, age-related declines in melatonin production, and the efficacy of exogenous melatonin and MT1/MT2 receptor agonists (ramelteon) for sleep disturbances in aging and Alzheimer's disease populations.
What was found
No quantitative values or effect estimates were reported in the abstract. Endogenous melatonin secretion decreases with age and is severely disrupted in Alzheimer's disease. General surveys across all age groups showed no clinically meaningful effects on sleep quality, efficiency, or latency, but clinical trials in elderly insomniacs and Alzheimer's disease patients repeatedly found exogenous melatonin effective for improving sleep.
Why it matters
This synthesis suggests that exogenous melatonin acts selectively rather than as a universal hypnotic, offering benefit primarily when endogenous production is deficient.
Limits
The abstract provides no sample sizes, study counts, dosages, or numerical outcomes. As a narrative review, it lacks systematic search criteria, quality appraisal, and meta-analytic pooling.
Cited by
- supports Melatonin production in the pineal gland declines with age, starting around 40 years old.